Fondaparinux Sodium

Drug #1670

Fondaparinux sodium is a synthetic pentasaccharide that inhibits activated factor X (clotting factor). Fondaparinux sodium is used for the prophylaxis of venous thromboemolism in patients undergoing major orthopaedic surgery of the legs.

← Previous drug Next drug →

Primary Characteristics

Non-proprietary name: Fondaparinux Sodium.

Molecular structure of Fondaparinux Sodium

Pharmacokinetics

Distribution: Fondaparinux Sodium has a volume of distribution is 7-11L. plasma protein binding is 94%.

Elimination: plasma half-life is 17-21hrs.

Indications

Fondaparinux Sodium is primarily indicated in conditions like Abdominal surgery prophylaxis, Deep vein thrombosis, Prophylaxis of deep vein thrombosis (in medical patients), Pulmonary embolism.

Contraindications

Fondaparinux Sodium is contraindicated in conditions like Renal impairment, Bleeding, Hypersensitivity to the drug, Bacterial endocarditis.

Dosage

Fondaparinux Sodium's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
2.5 mg	2.5 mg	Every 24h	SC	DVT Prophylaxis: After hemostasis is established, give the initial dose 6 to 8 h after surgery. Usual duration of therapy is 5 to 9 days (up to 11 days following hip or knee replacement surgery or up to 10 days following abdominal surgery). An extended prophylaxis course of up to 24 additional days (up to 32 days total) is recommended following hip fracture surgery.
5 mg	5 mg	Every 24h	SC	Acute DVT and Acute PE Treatment: Subcutaneous 5 mg if body weight less than 50 kg, 7.5 mg if body weight 50 to 100 kg, and 10 mg if body weight more than 100 kg, given once daily. Continue treatment for at least 5 days and until a therapeutic oral anticoagulant effect is established (INR 2 to 3). Initiate coadministration of warfarin as soon as possible, usually within 72 h. Usual duration of therapy is 5 to 9 days (up to 26 days).
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

None recorded.

Side Effects

Fondaparinux Sodium is known to cause more or less tolerable side effects which are usually transient. These include Anemia, Bleeding , Constipation , Diarrhea, Fever, Headache, Nausea, Pain , Rashes .

Warnings / Precautions

Fondaparinux Sodium injection is not intended for intramuscular administration.Should be used with caution in patients with moderate renal impairment.Renal function should be assessed periodically in patients receiving Fondaparinux Sodium.The drug should be discontinued immediately in patients who develop severe renal impairment while on therapy.Fondaparinux Sodium Injection, like other anticoagulants, should be used with extreme caution in conditions with increased risk of hemorrhage, such as congenital or acquired bleeding disorders, active ulcerative and angiodysplastic gastrointestinal disease, hemorrhagic stroke, or shortly after brain, spinal, or ophthalmological surgery, or in patients treated concomitantly with platelet inhibitors.

Interference in Pathology

Fondaparinux Sodium may interfere in the diagnosis of Elevation in ALT or AST, Stool testing, Complete blood cell count.

Available Brands

Click on a strength to view available brands.

Single Ingredient

Inj

1.5 mg/ml 10 mg/ml 5 mg/ml 7.5 mg/ml

Storage Conditions

Fondaparinux Sodium should be stored Inj.

Drug Classification

1.10.2 — Anticoagulants/Platelet deaggregators

Manufacturers

Manufacturers of Fondaparinux Sodium in Pakistan:

GSK